Viatris Q2 2026: Revenue $3.8B (+5%), GAAP net loss $119M, raises full-year guidance

Viatris Inc

Total revenues $3.8B, up 5% reported and 3.5% operationally vs Q2 2025; GAAP net loss $119M.
Adjusted EBITDA $1.2B, up 8% operationally; gross leverage ratio reduced to 2.9x.
Raised 2026 financial guidance midpoints for all metrics; expects balanced H2.
Returned ~$550M to shareholders including ~$270M share repurchases through early August.
Pipeline milestones: U.S. FDA approval of Gwyn Lo; sale of global rights to Tyrvaya.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.